verteporfin PDT
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome
Trial Timeline
— → Mar 1, 2004
NCT ID
NCT00049959About verteporfin PDT
verteporfin PDT is a phase 3 stage product being developed by Novartis for Basal Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00049959. Target conditions include Basal Cell Carcinoma, Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00049959 | Phase 3 | Terminated |
Competing Products
20 competing products in Basal Cell Carcinoma